1-5 of 5
Helen Ye
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Combination therapy of recombinant interleukin-2 and targeted small molecule receptor tyrosine kinase inhibitors (BAY 43-9006 or SU11248) augment anticancer activity in preclinical tumor models

Daniel Lopes de Menezes, Kimberly Denis-Mize, James Chou, Yan Tang, Helen Ye, John Kunich, Katherine Porth, Laurence Elias, Bahija Jallal, Sharon Aukerman
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 972.
Published: 01 May 2007
View article
Journal Articles

TKI258 is an effective multi-targeted receptor tyrosine kinase (RTK) inhibitor against xenograft models of human melanoma.

Katherine Rendahl, Daniel Menezes, Paul Hollenbach, Yan Tang, Helen Ye, Debbie Swinarski, XiaoHong Niu, Tinya Abrams, Michel Faure, Natasha Aziz, Michael Rowe, Pablo Garcia, Jocelyn Holash, Nancy Pryer, Carla Heise
Journal: Cancer Research
Cancer Res (2007) 67 (9_Supplement): 3258.
Published: 01 May 2007
View article
Journal Articles

CHIR-265, a novel inhibitor that targets B-Raf and VEGFR, shows efficacy in a broad range of preclinical models

Eleni Venetsanakos, Darrin Stuart, Nguyen Tan, Helen Ye, Fernando Salangsang, Kimberley Aardalen, Michel Faure, Carla Heise, Dirk Mendel, Bahija Jallal
Journal: Cancer Research
Cancer Res (2006) 66 (8_Supplement): 1140.
Published: 15 April 2006
View article
Journal Articles

Proleukin (aldesleukin, rhIL-2) immunotherapy in combination with rituximab following initial CHOP/rituximab treatment induces highly durable complete responses in a xenograft model of indolent B-cell Non-Hodgkin’s lymphoma

Daniel E. Lopes de Menezes, Kimberly Denis-Mize, Carla Heise, Arnold B. Gelb, Helen Ye, Yan Tang, John Kunich, Sandra Milan, Laurence Elias, Susan E. Wilson, Lea Aukerman, Bahija Jallal
Journal: Cancer Research
Cancer Res (2005) 65 (9_Supplement): 131.
Published: 01 May 2005
View article
Journal Articles

Durable in vivo target modulation with CHIR258, a small molecule inhibitor of growth factor tyrosine kinase receptors, is associated with potent antitumor efficacy using various dosing schedules.

Sang Hoon Lee, Daniel Menezes, Jayesh Vora, Helen Ye, Jing Peng, Evelyn Garrett, Cheryl Goldbeck, Lea Aukerman, Carla Heise
Journal: Cancer Research
Cancer Res (2004) 64 (7_Supplement): 490.
Published: 01 April 2004
View article